FGFR-话题@MedSci

#FGFR#

30篇内容 | 2423人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2207472, encodeId=ffec220e472ed, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a> <a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a> <a href='/topic/show?id=0de5290588c' target=_blank style='color:#2F92EE;'>#免疫检查点抑制剂#</a>, objectTitle=Pharmacol：FGFR改变对尿路上皮癌患者接受免疫检查点抑制剂治疗预后和疗效的Meta分析, objectType=article, longId=828036, objectId=a7828280365a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240529/1716991610244_6145188.jpg, objectUrl=/article/show_article.do?id=a7828280365a, replyNumber=0, likeNumber=115, createdTime=2024-05-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a7828280365a, moduleTitle=Pharmacol：FGFR改变对尿路上皮癌患者接受免疫检查点抑制剂治疗预后和疗效的Meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7828280365a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2207273, encodeId=8e51220e27386, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a> <a href='/topic/show?id=32e7114966c6' target=_blank style='color:#2F92EE;'>#培米加替尼#</a> <a href='/topic/show?id=215f11496e1b' target=_blank style='color:#2F92EE;'>#Ⅱ期篮子试验#</a>, objectTitle=NAT MED | 培米加替尼治疗多种FGFR基因变异实体瘤的II期篮子试验, objectType=article, longId=828022, objectId=d8a5828022cf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240529/1716965554095_92910.png, objectUrl=/article/show_article.do?id=d8a5828022cf, replyNumber=0, likeNumber=93, createdTime=2024-05-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d8a5828022cf, moduleTitle=NAT MED | 培米加替尼治疗多种FGFR基因变异实体瘤的II期篮子试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8a5828022cf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1483082, encodeId=d771148308212, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=107, createdTime=2022-05-25, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483081, encodeId=ed47148308165, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, objectType=article, longId=723401, objectId=df51e23401fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df51e23401fa, replyNumber=0, likeNumber=124, createdTime=2022-04-05, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df51e23401fa, moduleTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df51e23401fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483080, encodeId=dfd7148308099, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, objectType=article, longId=215464, objectId=286f215464c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286f215464c0, replyNumber=0, likeNumber=77, createdTime=2021-08-10, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286f215464c0, moduleTitle=Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286f215464c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483079, encodeId=c08b14830e98b, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究, objectType=article, longId=214990, objectId=95022149908f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95022149908f, replyNumber=0, likeNumber=83, createdTime=2021-07-30, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95022149908f, moduleTitle=Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95022149908f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483078, encodeId=e27d14830e8cb, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Eur Urol Focus：基于人工智能的常规组织学检测膀胱癌FGFR3突变状态, objectType=article, longId=210910, objectId=93ee2109107f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93ee2109107f, replyNumber=0, likeNumber=142, createdTime=2021-05-08, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93ee2109107f, moduleTitle=Eur Urol Focus：基于人工智能的常规组织学检测膀胱癌FGFR3突变状态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93ee2109107f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483077, encodeId=4a2b14830e77c, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价, objectType=article, longId=206525, objectId=468b20652504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468b20652504, replyNumber=0, likeNumber=88, createdTime=2021-02-02, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468b20652504, moduleTitle=Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468b20652504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483076, encodeId=89a814830e67a, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Acta Neuropathologica: 在一系列83例H3F3A K27M突变的弥漫性中线胶质瘤中，FGFR1突变与较好的预后相关 , objectType=article, longId=206259, objectId=280e2062593b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=280e2062593b, replyNumber=0, likeNumber=94, createdTime=2021-01-27, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=280e2062593b, moduleTitle=Acta Neuropathologica: 在一系列83例H3F3A K27M突变的弥漫性中线胶质瘤中，FGFR1突变与较好的预后相关 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=280e2062593b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483075, encodeId=cdd714830e501, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Clin Cancer Res：抑制FGFR可克服皮肤鳞状细胞癌对EGFR靶向治疗的耐药性, objectType=article, longId=206215, objectId=5d49206215f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d49206215f3, replyNumber=0, likeNumber=99, createdTime=2021-01-26, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d49206215f3, moduleTitle=Clin Cancer Res：抑制FGFR可克服皮肤鳞状细胞癌对EGFR靶向治疗的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d49206215f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483074, encodeId=a0f114830e46a, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现, objectType=article, longId=193179, objectId=833e1931e9c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=833e1931e9c2, replyNumber=0, likeNumber=131, createdTime=2020-05-01, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=833e1931e9c2, moduleTitle=AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=833e1931e9c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483073, encodeId=c63e14830e341, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=AACR 2020：大样本NSCLC中的FGFR基因突变结果发布, objectType=article, longId=193107, objectId=ee7719310e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee7719310e83, replyNumber=0, likeNumber=124, createdTime=2020-04-30, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee7719310e83, moduleTitle=AACR 2020：大样本NSCLC中的FGFR基因突变结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee7719310e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483072, encodeId=208714830e2d7, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性, objectType=article, longId=192882, objectId=1354192882ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1354192882ef, replyNumber=0, likeNumber=105, createdTime=2020-04-25, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1354192882ef, moduleTitle=Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1354192882ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483071, encodeId=13dd14830e1d8, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=FDA批准胆管癌FGFR靶向药pemigatinib获批, objectType=article, longId=192611, objectId=3a2319261150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a2319261150, replyNumber=0, likeNumber=86, createdTime=2020-04-22, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a2319261150, moduleTitle=FDA批准胆管癌FGFR靶向药pemigatinib获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a2319261150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483070, encodeId=a02e14830e056, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌, objectType=article, longId=191608, objectId=8be819160868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8be819160868, replyNumber=0, likeNumber=104, createdTime=2020-04-08, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8be819160868, moduleTitle=Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8be819160868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483069, encodeId=4f4c1483069b1, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Sci Signal：不同的FGFRs通过不同的配体激活不同的信号通路指导不同的肺部功能发育, objectType=article, longId=189410, objectId=746418941056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=746418941056, replyNumber=0, likeNumber=129, createdTime=2020-03-07, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=746418941056, moduleTitle=Sci Signal：不同的FGFRs通过不同的配体激活不同的信号通路指导不同的肺部功能发育, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=746418941056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483068, encodeId=8517148306820, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查, objectType=article, longId=184090, objectId=d0cc1840903e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0cc1840903e, replyNumber=0, likeNumber=0, createdTime=2019-12-05, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0cc1840903e, moduleTitle=成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0cc1840903e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483067, encodeId=09a1148306eaa, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌, objectType=article, longId=183714, objectId=e945183e14f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e945183e14f6, replyNumber=0, likeNumber=82, createdTime=2019-11-29, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e945183e14f6, moduleTitle=FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e945183e14f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483066, encodeId=a48b14830666b, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Lancet Oncol：Rogaratinib治疗多种FGFR mRNA高表达晚期肿瘤, objectType=article, longId=177581, objectId=565d1e7581d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=565d1e7581d5, replyNumber=0, likeNumber=91, createdTime=2019-08-15, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=565d1e7581d5, moduleTitle=Lancet Oncol：Rogaratinib治疗多种FGFR mRNA高表达晚期肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=565d1e7581d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1483065, encodeId=14581483065a8, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, objectTitle=Sci Rep：膀胱癌中ETV5与FGFR3和Hippo信号途径有关, objectType=article, longId=164570, objectId=02c51645e052, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02c51645e052, replyNumber=0, likeNumber=113, createdTime=2019-04-20, rootId=0, userName=12498c24m71暂无昵称, userId=31fb7872570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02c51645e052, moduleTitle=Sci Rep：膀胱癌中ETV5与FGFR3和Hippo信号途径有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02c51645e052)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FGFR

2020-05-29

梅斯管理员

#FGFR# #尿路上皮癌# #免疫检查点抑制剂#

Pharmacol：FGFR改变对尿路上皮癌患者接受免疫检查点抑制剂治疗预后和疗效的Meta分析

2024-05-30发表于上海

梅斯管理员

#FGFR# #培米加替尼# #Ⅱ期篮子试验#

NAT MED | 培米加替尼治疗多种FGFR基因变异实体瘤的II期篮子试验

2024-05-29发表于上海

12498c24m71暂无昵称

#FGFR#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2022-05-25

12498c24m71暂无昵称

#FGFR#

Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效

2022-04-05

12498c24m71暂无昵称

#FGFR#

Lancet Gastroenterol Hepatol：Infigratinib在FGFR2融合或重排的晚期胆管癌中的疗效和安全性

2021-08-10

12498c24m71暂无昵称

#FGFR#

Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究

2021-07-30

12498c24m71暂无昵称

#FGFR#

Eur Urol Focus：基于人工智能的常规组织学检测膀胱癌FGFR3突变状态

2021-05-08

12498c24m71暂无昵称

#FGFR#

Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价

2021-02-02

12498c24m71暂无昵称

#FGFR#

Acta Neuropathologica: 在一系列83例H3F3A K27M突变的弥漫性中线胶质瘤中，FGFR1突变与较好的预后相关

2021-01-27

12498c24m71暂无昵称

#FGFR#

Clin Cancer Res：抑制FGFR可克服皮肤鳞状细胞癌对EGFR靶向治疗的耐药性

2021-01-26

12498c24m71暂无昵称

#FGFR#

AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现

2020-05-01

12498c24m71暂无昵称

#FGFR#

AACR 2020：大样本NSCLC中的FGFR基因突变结果发布

2020-04-30

12498c24m71暂无昵称

#FGFR#

Cell Death Dis：miR-486-3p通过FGFR4及EGFR调节肝癌细胞对索拉非尼的耐受性

2020-04-25

12498c24m71暂无昵称

#FGFR#

FDA批准胆管癌FGFR靶向药pemigatinib获批

2020-04-22

12498c24m71暂无昵称

#FGFR#

Lancet oncol：Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌

2020-04-08

12498c24m71暂无昵称

#FGFR#

Sci Signal：不同的FGFRs通过不同的配体激活不同的信号通路指导不同的肺部功能发育

2020-03-07

12498c24m71暂无昵称

#FGFR#

成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查

2019-12-05

12498c24m71暂无昵称

#FGFR#

FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌

2019-11-29

12498c24m71暂无昵称

#FGFR#

Lancet Oncol：Rogaratinib治疗多种FGFR mRNA高表达晚期肿瘤

2019-08-15

12498c24m71暂无昵称

#FGFR#

Sci Rep：膀胱癌中ETV5与FGFR3和Hippo信号途径有关

2019-04-20